Proteon Pharmaceuticals S.A.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2011-02-01
Share capital
1,243,961.60 PLN
Registered address
Tylna 3A, 90-364 Łódź, Poland
Email
Electronic delivery address
AE:PL-93353-53390-CEGRH-24

Financials

Revenue history (in k)

Filing timeliness

No financial statement for 2025 – the filing deadline has passed. All were audited by a statutory auditor.

  • 2025not filed
  • 202426/06/2025
  • 202309/07/2024
  • 202205/07/2023
  • 202111/07/2022
  • 202020/07/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2024.

Top 10%
Voivodeship · Łódzkie4,179 / 23,462
Top 18%
Country · Poland80,988 / 496,512
Top 16%

Results vs industry

Revenue
This companyUSD 2.03mMedianUSD 56.72kAverageUSD 2.72m
Net profit
This companyUSD -8.72mMedianUSD -1.27kAverageUSD -93.01k
Operating costs
This companyUSD 7.77mMedianUSD 66.48kAverageUSD 2.68m
Assets
This companyUSD 12.66mMedianUSD 134.71kAverageUSD 3.04m

Industry

Website technology

Website
  • WordPress

Trademarks

The company holds 5 active trademarks registered with the Polish Patent Office. The first mark was filed in 2011.

MarkNumberClassesStatusProtected until
BAFACAM (word)Z.5376895Protected Dec 13, 2031
AmKur Bio (word)Z.5303621, 5Protected Jun 16, 2031
Proteon Zdrowie Z.51551344Protected Jul 2, 2030
BAFADOR (word)Z.4252625Protected Feb 25, 2034
BAFASAL (word)Z.3867985Protected Jun 16, 2031
MarkProtected until
BAFACAM (word)Dec 13, 2031
AmKur Bio (word)Jun 16, 2031
Proteon Zdrowie Jul 2, 2030
BAFADOR (word)Feb 25, 2034
BAFASAL (word)Jun 16, 2031

Authorized Representatives

Manner of representation

In the case of a one-person management board, one member of the management board acting independently is authorized to make declarations of will on behalf of the company. In the case of a management board consisting of two or more members, two members of the management board acting jointly are authorized to make declarations of will on behalf of the company.

Supervisory board

Sergejs Iljasenko – Supervisory Board Member
Paweł Kowalczyk age 45 – Supervisory Board Member

Beneficial owners

Person

Subsidiaries

NameStake
100%

Bank accounts

Was a VAT taxpayer from 2005-06-02 to 2026-09-03.

Reason for removal: Art. 96 ust. 9a pkt 2 (VAT returns not filed for 3 consecutive months or a quarter)

Debt

5 active proceedings recorded in KRZ.

Registration dateProceeding typeStatus
Feb 3, 2026
Petition to declare entrepreneur bankruptcy
Joined
Dec 15, 2025
Petition to declare entrepreneur bankruptcy
In progress
Jan 26, 2026
Complaint against a decision in accelerated arrangement proceedings
Closed
Jul 29, 2025
Accelerated arrangement proceedings
Closed
Jul 2, 2025
Petition to open accelerated arrangement proceedings
Closed

MSiG notices

47 notices recorded in the Court and Commercial Gazette (MSiG).

Publication dateEvent
Feb 17, 2026Shareholders' meeting convened
Jan 29, 2026Shareholders' meeting convened
Nov 27, 2025Shareholders' meeting convened
Nov 13, 2025Shareholders' meeting convened
Oct 22, 2025Shareholders' meeting convened

Public aid

15 public aid cases recorded, with a total value of $12,464,408.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
–
Regional investment aid
–
Aid for SME access to finance — risk finance aid
–

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Medapp S.A.
Biotechna S.A.
Read-Gene S.A.
Skinlab P.S.A.
EIT Rawmaterials Clc East sp. z o.o.
Centrum Innowacji I Wdrożeń Bio-Inwest sp. z o.o.
COS Lab P.S.A.
Syvento sp. z o.o.
WPD Pharmaceuticals sp. z o.o.
Uvera S.A.

Change history

DateEvent
2025-04-07Share capital increase
2024-08-21Share capital increase
2024-07-22Share capital increase
2024-07-11Share capital increase
2023-03-17Share capital increase

FAQ

Last updated: 2026-10-07